tbuckley/cabot-search huggingface dataset:
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia
Authors: I Alvarez-Twose, P Martínez-Barranco, J Gotlib, A García-Montero, J M Morgado, M Jara-Acevedo, J D Merker, F J Peñalver, A Matito, Y Hou, L Sánchez-Muñoz, A Mayado, M Mollejo, L Escribano, A Orfao
Journal: Leukemia (2016)
Der(6)t(1;6)(q21–23;p21.3): The most specific chromosomal translocation in myelofibrosis with myeloid metaplasia
Authors: D. Dingli, V. J. Mahaffey, J. L. Spurbeck, G. W. Dewald, A. Tefferi
Journal: Journal of Clinical Oncology (2005)

6548 Background: Chromosome lesions are detected in approximately 50% of patients with myeloid metaplasia with myelofibrosis (MMM) and often involve chromosomes 1, 7, 8, 13, 17 and 20. However, none of these abnormalities are disease specific. In a recent prospective study of 81 patients with MMM, we identified 3 patients with an unbalanced translocation between chromosomes 1 and 6. Since translocations between these two chromosomes have not well described, we surveyed the entire Mayo Clinic cytogenetic data base for the specific translocation. Methods: All patients with translocations between chromosomes 1 and 6 were identified and all breakpoints reviewed. Chromosome breakpoints were matched with the corresponding hematologic diagnosis looking for clustering of chromosome breaks and specific disease states. Relevant clinical and laboratory data were also extracted. Results: Among 17,791 cytogenetic studies performed over a 15-year period, we identified 25 patients with a t(1;6) karyotypic abnormality. Of these, 12 patients had a unique unbalanced translocation between chromosomes 1 and 6 leading to an abnormal derivative chromosome 6 with specific breakpoints: der(6)t(1;6)(q21–23;p21.3). Interestingly, all these 12 patients (7 males; median age 65.5 years) carried the diagnosis of MMM including 10 with agnogenic myeloid metaplasia, one each with post-polycythemic and post-thrombocythemic myeloid metaplasia. Nine of the 12 patients displayed complex karyotypes, whereas der(6) was the sole abnormality identified in 3 patients. Eleven patients had splenomegaly and 3 required splenectomy. The median survival of this cohort was 7.4 years. One patient transformed to acute myeloid leukemia. Conclusion: Der(6)t(1;6)(q21–23;p21.3) is the most specific chromosomal abnormality in MMM and might be a marker of an underlying genetic mutation that is integral to disease pathogenesis. No significant financial relationships to disclose.
Metastatic Midgut Carcinoid in the Myocardium
Authors: Jakub Bukowczan, Konstantinos B. Lois, Jane Skinner, George Petrides, Robert Andrew James, Petros Perros
Journal: Clinical Nuclear Medicine (2015)

Metastasis of neuroendocrine tumor to the myocardium is rare. We present a case of 64-year-old woman, who presented initially with abdominal pain and large adnexal mass. The image-guided biopsy showed low-grade neuroendocrine tumor with Ki67 less than 2% within the ovarian tissue. CT staging revealed bilateral adnexal masses, liver metastases, and primary lesion in the terminal ileum. Octreoscan showed marked tracer uptake within the lower esophagus not related to obvious mass on CT scan; the echocardiography confirmed the presence of a 2.7 cm LV/LA mass. In this case, close correlation between ECHO and the octreoscan obviated need for myocardial biopsy.
The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide
Authors: W. Taal, D. Brandsma, H. G. de Bruin, J. E. Bromberg, A. T. Swaak-Kragten, W. M. Eijkenboom, M. J. van den Bent
Journal: Journal of Clinical Oncology (2007)

2009 Background: Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for newly diagnosed glioblastoma. The occurrence of pseudo-progression at the end of RT is an often-mentioned phenomenon, but the actual incidence is unknown. It is also unclear if this is only a radiological phenomenon or is accompanied by clinical signs and symptoms. We retrospectively assessed this phenomenon in a cohort of patients treated with chemo-irradiation with temozolomide (RT/TMZ). Methods: The pre- and post-chemo-radiotherapy brain CT’s and MRI’s from all patients treated with RT/TMZ for a malignant glioma in the Daniel den Hoed Cancer Center between 2000 and 2005 were reviewed. Treatment consisted of 60 Gy RT in 6 weeks combined with daily TMZ (75mg/m2/day), followed after 4 weeks by 6 cycles of TMZ (150–200 mg/m2/day 1–5 every 4 weeks). Scans were made prior to the start of RT, four weeks after the end of RT and thereafter every three months. Macdonald’s criteria were used to assess the response. In addition information was collected on clinical signs and symptoms, dexamethasone dose, histology, and survival. Results: Sixty-five patients were identified; 54 had been diagnosed with a GBM. Mean age was 48 years and 42 were male. In 23 patients the first follow-up scan 4 weeks after the end of RT showed progression as compared to the pre-RT imaging. This was accompanied by clinical deterioration in12 patients. All patients continued with adjuvant TMZ. In 12 of these 23 patients the MRI and clinical signs and symptoms stabilized or improved in the months thereafter. In 8 of these 12 patients a response was observed without additional treatment other than TMZ. In none of these cases changes in dexamethasone dose could explain the observed MRI changes. Conclusions: In up to 50% of high grade glioma patients treated with chemo-irradiation with TMZ and a progressive MRI lesion immediately after RT suffer from pseudo-progression; this was observed in 12 out of 65 patients. These data support the notion to continue TMZ in case of progressive lesions immediately after RT/TMZ. Studies on recurrent gliomas that accept patients with progressive lesions directly after chemo-radiation will lead to an overestimation of the results. No significant financial relationships to disclose.
Urinary Excretion of Fourteen Amino Acids by Normal and Cancer Subjects&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Charles H. Eades, Jr., Robert L. Pollack
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Urinary Excretion of Fourteen Amino Acids by Normal and Cancer Subjects Get access Charles H. Eades, Jr., Charles H. Eades, Jr. Department of Biochemistry, University of Tennessee, Memphis, Tenn. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert L. Pollack Robert L. Pollack Department of Biochemistry, University of Tennessee, Memphis, Tenn. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 3, December 1954, Pages 421–427, https://doi.org/10.1093/jnci/15.3.421 Published: 01 December 1954 Article history Received: 28 July 1954 Published: 01 December 1954
Applying the Principles of McDonaldization to Medicine
Authors: Jagannadha R. Avasarala
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study
Authors: H. Nakayama, Y. Kato, M. Tsuboi, S. Okumura, H. Daisaki, H. Uehara, S. Adachi, M. Yoshimura, M. Okada
Journal: Journal of Clinical Oncology (2009)

7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy. We examined the malignancy grade of small lung ADs using FDG-PET/CT (PET), in addition to high-resolution CT (HRCT) and pathologic evaluation in a multicenter setting. Methods: A total of 204 patients with cT1N0M0 AD underwent PET and HRCT, followed by complete resection with lymph node dissection. The associations between components of bronchioloalveolar carcinoma (BAC) on pathologic examination and maximum standardized uptake value (maxSUV) on PET, ground-glass opacity (GGO) ratio and tumor disappearance rate (TDR) on HRCT were examined, and these findings were analyzed in relation to pathologic features and surgical outcomes. To reduce the errors in PET machines used for this analysis, maxSUV data were adjusted using an anthropomorphic body phantom of the NEMA standards (corrected maxSUV). Results: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade. MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival. There were no significant differences in the values between maxSUV and corrected maxSUV. Although BAC ratio was significantly associated with maxSUV, GGO ratio and TDR (all p&lt;0.0001), the degree of association with maxSUV (R2=0.2533) was weaker than that with GGO (R2=0.5843) ratio or TDR (R2=0.5123). Conclusions: A higher maxSUV reflects an aggressive malignant behavior of cT1N0M0 ADs, independently of BAC component. Assessment by PET in addition to HRCT is useful for selection of the appropriate treatment strategy for small lung AD. [Table: see text] No significant financial relationships to disclose.
What is the value added of patient reported outcomes relative to physician rated symptom assessments?
Authors: S. J. Mandrekar, M. M. Huschka, P. L. Schaefer, J. R. Jett, A. A. Adjei, J. A. Sloan
Journal: Journal of Clinical Oncology (2006)

8580 Background: This pooled analysis examined the relationship between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between changes in QOL and patient-reported adverse events (AE). Methods: Data from six lung cancer clinical trials involving 358 patients were pooled. All trials incorporated the UNISCALE and one of three multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. A clinically significant decline (CSD) in QOL was defined as a 10-point drop from baseline. A CSD in AE was defined as a change from ≤ grade 2 at baseline to ≥ grade 3 post-baseline. Spearman rank correlations and Bland-Altman approach were used to assess agreement. The Kaplan-Meier method was used to evaluate the time to the first occurrence of a severe (grade 3+) AE and first CSD in QOL. Results: Correlations between the UNISCALE and multi-item assessments were modest (rho=0.49–0.66). At least one 10-point decline in the UNISCALE and multi-item assessments were reported by 58% and 40% respectively. At least one severe AE was reported in 44% of patients post-baseline. The percent agreement between experiencing a severe AE and a CSD in QOL was 49% and 59% for UNISCALE and the multi-item tools. For individual AE, the percent agreement between a CSD in AE and a CSD in QOL ranged from 37% to 50% for UNISCALE and 44% to 69% for the multi-item tools. The median time to the first CSD in QOL for UNISCALE and multi-item tools was 67 and 142 days respectively. The median time to the first occurrence of a severe AE was 304 days. Conclusions: QOL and AE provide quantifiably different information. A 10-point decline in QOL occurs earlier than CTC AE reporting. Patient reported outcomes may be more sensitive in identifying clinically relevant problems than physician rated symptom assessments. No significant financial relationships to disclose.
Efficacy and Safety of Gemcitabine-Based Combination Regimens in Patients with Extranodal Natural Killer/T Cell Lymphoma, Nasal Type
Authors: Jingjing Wang, Mei Dong, Xiaohui He, Weihu Wang, Peng Liu, Jianliang Yang, Yan Qin, Lin Gui, Sheng Yang, Yexiong Li, Yuankai Shi, Lugui Qiu
Journal: Blood (2014)
PTU-307 The hidden endoscopic burden of sleeve gastrectomy and its comparison with roux-en-y gastric bypass
Authors: K Arndtz, H Steed, J Hodson, S Manjunath
Journal: Gut (2015)

<h3>Introduction</h3> In the UK, 61.9% of adults are obese and associated co-morbidity is estimated to cost the NHS £5 billion annually.<sup>1</sup>NICE recommends bariatric surgery as a treatment option for some obese patients.<sup>2</sup>Complications of bariatric surgery are commonly diagnosed and managed by the use of endoscopic procedures, such as endoscopic stent insertion or pneumatic balloon dilatation. This study aims to assess the burden of bariatric surgery-related endoscopy at our hospital, one of the main centres for bariatric surgery in the West Midlands. This is a parallel and enhanced study to “The Hidden Endoscopic burden of Roux-en-Y Gastric Bypass” (RYGB) published in Frontline Gastroenterology in 2013<sup>3</sup>and now also includes data for sleeve gastrectomy. <h3>Method</h3> The retrospective study included all 211 patients undergoing sleeve gastrectomy over a 34 month period. We also utilised the previously collected data for the RYGB patient cohort which included 553 patients over 29 months. In both cohorts, the minimum follow up was 180 days. We searched our hospital endoscopic database for patients who underwent post-operative endoscopy for indications felt to be surgery related. <h3>Results</h3> 16.6% of the sleeve gastrectomy patients required post-operative gastroscopy, of which 11.4% of procedures were therapeutic. This compares to 20.4% of the RYGB cohort of which 50.4% of procedures were therapeutic (p &lt; 0.001). 1.9% of sleeve gastrectomy patients encountered a post-operative staple-line leak and collectively required 29 procedures including 8 stent insertions. One patient also developed stricturing (0.47%) requiring 18 pneumatic dilatations. 11.4% of the RYGB cohort developed an anastomotic stricture requiring 57 balloon dilatation procedures. To date, these procedures have accumulated a cost of £114,458 in endoscopy tariffs, or £105 per RYGB and £267 per sleeve gastrectomy performed. <h3>Conclusion</h3> Bariatric surgery can have significant complications in terms of patient morbidity and financial cost. Having a local bariatric surgery service increases the demand for endoscopic procedures in our hospital, both in investigating for and dealing with post-operative complications. Provision of extra resources and expertise needs to be taken into account. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> NICE Guidance 2014. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. CG189. London Department of Health Policy. Reducing obesity and improving diet. 2013. [Online]. Available from: https://www.gov.uk/government/policies/reducing-obesity-and-improving-diet[Accessed 1st July 2014] Steed H, Golar H, Manjunath S. The hidden endoscopic burden of Roux-en-Y gastric bypass surgery. Frontline Gastroenterol. 2013;4:69–72
Replicative Epithelial Cell Cultures From Normal Human Prostate Gland: Brief Communication2
Authors: J. F. Lechner, K. Shankar Narayan, Y. Ohnuki, M. S. Babcock, L. W. Jones, M. E. Kaighn
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Replicative Epithelial Cell Cultures From Normal Human Prostate Gland: Brief Communication Get access J. F. Lechner, J. F. Lechner 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Shankar Narayan, K. Shankar Narayan 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar Y. Ohnuki, Y. Ohnuki 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar M. S. Babcock, M. S. Babcock 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar L. W. Jones, L. W. Jones 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar M. E. Kaighn M. E. Kaighn 3Pasadena Foundation for Medical Research, Pasadena, Calif. 91101 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 4, April 1978, Pages 797–801, https://doi.org/10.1093/jnci/60.4.797 Published: 01 April 1978 Article history Received: 28 September 1977 Accepted: 31 October 1977 Published: 01 April 1978
BRAF mutation by age-decade and body mass index in metastatic melanoma.
Authors: A. M. Menzies, L. Visintin, M. D. Chatfield, M. S. Carlino, J. R. Howle, R. A. Scolyer, J. F. Thompson, R. F. Kefford, G. V. Long
Journal: Journal of Clinical Oncology (2011)

8507 Background: Melanoma disproportionately affects those under 40yr compared with other solid tumors. Oncogenic BRAF mutations occur at an overall rate of approximately 50%, and are associated with younger age. No study to date has examined decade-specific BRAF mutation rates, a clinically relevant parameter in the era of MAPK-pathway targeting therapy. Obesity is associated with an increased risk of melanoma, however the association of body mass index (BMI) with BRAF mutation status is unknown. We aimed to determine the decade-specific BRAF mutation rate and genotype in metastatic melanoma, and explore its relationship with BMI. Methods: 312 consecutive BRAF-tested patients with unresectable stage IIIC and IV melanoma were analysed. Tumour samples were screened by high-resolution melt curve analysis of BRAF exon 15 with abnormal results confirmed by DNA sequencing. Data were collected to assess demographic and anthropometric variables, and details of the age at metastatic disease diagnosis. Results: 46% of the 312 patients had a BRAF mutation. Of these, 73% were V600E, 19% V600K, and 8% other genotypes. The BRAF mutation rate decreased with increasing age, particularly after age 40 (p<0.001, χ² test). Amongst those with a BRAF mutation, there was a difference in age distribution and BRAF mutation genotype (p=0.05, Kruskal Wallis test). In the subgroup of younger patients (≤40yr), there was a significant difference in BMI between BRAF mutant and wild-type (median BMI 24.3 v 28.8, p=0.03, Mann-Whitney test). Conclusions: In patients with metastatic melanoma, there is an inverse relationship between BRAF mutation rate and age. There is some evidence that BRAF mutation genotype varies with age, with V600E occurring more frequently at younger ages, and V600K at older. BRAF wild-type melanoma may be associated with higher BMI in patients ≤40yr. Phenotypic characterisation of molecular features will have increasing significance as targeted therapies develop, and may direct further research into the mechanisms of oncogenesis in melanoma. Age No. BRAF mutant V600E V600K 20-30 14 86% 83% 0% 31-40 30 80% 92% 8% 41-50 42 50% 76% 14% 51-60 58 41% 67% 29% 61-70 103 48% 71% 24% >70 65 22% 50% 21%
Association of Preoperative Narcotic Use With Postoperative Complications and Prolonged Length of Hospital Stay in Patients With Crohn Disease
Authors: Yi Li, Luca Stocchi, Deepa Cherla, Xiaobo Liu, Feza H. Remzi
Journal: JAMA Surgery (2016)

The use of narcotics among patients with Crohn disease (CD) is endemic.To evaluate the association between preoperative use of narcotics and postoperative outcomes in patients with CD.Patients undergoing abdominal surgery for CD at a tertiary referral center between January 1998 and June 2014 were identified from an institutional prospectively maintained CD database.Primary end points were overall morbidity, postoperative hospital length of stay, and readmission. Univariate and multivariate analyses were used to assess possible associations between postoperative outcomes and demographic and clinical variables, including preoperative narcotic use.Of the 1331 patients included, the mean age for patients who had at least 1 pharmacy claim for narcotics within 1 month before surgery was 41.5 years and 41.1 years for patients without a pharmacy claim. Of 1461 abdominal operations for CD, 267 (18.3%) were performed on patients receiving preoperative narcotics. Patients receiving narcotics were more likely to have a current smoking habit (P < .001) with perianal disease (P = .046) and undergoing treatment with biologics (P = .04). Patients with preoperative narcotic use had a longer mean (SD) length of stay (11.2 [8.9] vs 7.7 [5.5]; P < .001) and were more likely to develop postoperative complications (52.8% vs 40.8%; P < .001). Multivariable analysis indicated that preoperative narcotic use was the only independent risk factor associated with both postoperative morbidity (odds ratio = 1.36; 95% CI = 1.02-1.82; P = .04) and prolonged hospital stay (estimate = 2.91; SE = 0.44; P < .001). Subgroup analysis indicated that outpatient narcotic users had increased incidence of adverse postoperative outcomes compared with inpatient-only narcotic users.Preoperative use of narcotics in patients undergoing abdominal surgery for CD is associated with worse postoperative outcomes. Before starting regular narcotic use, patients with CD should be considered for surgical intervention.
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Authors: E Kokenberg, P Sonneveld, W Sizoo, A Hagenbeek, B Löwenberg
Journal: Journal of Clinical Oncology (1988)

In an attempt to identify pharmacokinetic factors that determine the response of acute myeloid leukemia (AML) patients to induction chemotherapy, we determined the concentrations of daunorubicin (DNR) and the main metabolite daunorubicinol (DOL) in vivo and particularly evaluated the concentrations in blood and bone marrow nucleated cells. Cell measurements were obtained in 37 evaluable patients during their first remission induction treatment with DNR and cytarabine (ara-C) and directly compared with the plasma distribution kinetics of DNR. We show that (1) plasma DNR concentrations do not correlate with DNR concentrations in bone marrow nucleated cells; but (2) plasma area under the curve (AUC) values of DNR correlate inversely (P less than .01) with AUC values of DNR in WBCs; (3) concentrations of DNR in WBCs correlate positively (P less than .01) with DNR concentrations in bone marrow nucleated cells; and (4) the concentrations of DNR in WBCs show a negative correlation (P less than .01) with the numbers of peripheral blast cells at diagnosis. We then tested whether the pharmacokinetic parameters had predictive value for the clinical outcome of therapy, but none of the plasma levels or WBC and bone marrow concentrations of DNR predicted treatment outcome. The inverse correlation between the concentrations of DNR in WBC and the numbers of peripheral blast cells suggests that the effective DNR concentrations achieved intracellularly are mainly a function of the tumor load so that lesser amounts of DNR accumulate intracellularly when the AML cell numbers in blood are higher.